On the safety of glucosamine sulfate in patients with insulin resistance

Cover Page

Cite item

Full Text

Abstract

Aim. Insulin resistance, metabolic syndrome and type 2 diabetes mellitus (T2DM) stimulate the development of chronic inflammation and make it difficult to rehabilitate patients with any comorbid pathology. In particular, T2DM impairs cartilage metabolism, leading to osteoarthritis (OA). For the treatment of arthropathogenic effects of diabetes mellitus, non-steroidal anti-inflammatory drugs (NSAIDs), drugs based on glucosamine sulfate (GS) and chondroitin sulfate (CS) are used. Materials and methods. Computer analysis of texts 21 777 publications. Results. GS is one of the safest OA therapies. Nexperimental and clinical studies have shown that HS can safely be used to treat OA in patients with type 2 diabetes. The anti-inflammatory effects of GS and the CS inhibition of O-acetylglucosamination processes by the molecules indicate the possibility of preventing the complications of type 2 diabetes. Conclusion. Despite the presence of the root "gluco" in the name of the GS, this substance does not stimulate the formation or progression of insulin resistance.

About the authors

Olga A. Gromova

Federal Research Center «Computer Science and Control» of the Russian Academy of Sciences; M.V.Lomonosov Moscow State University

Email: unesco.gromova@gmail.com
Center for Big Data Storage and Analysis Technologies; D. Sci. (Med.), Prof. Moscow, Russia

Ivan Iu. Torshin

Federal Research Center «Computer Science and Control» of the Russian Academy of Sciences; M.V.Lomonosov Moscow State University

Center for Big Data Storage and Analysis Technologies; Сand. Sci. (Chemical) Moscow, Russia

Aleksandr M. Lila

A.Nasonova Research Institute of Rheumatology

D. Sci. (Med.), Prof. Moscow, Russia

Anton V. Naumov

Pirogov Russian National Research Medical University

D. Sci. (Med.), Prof. Moscow, Russia

Konstantin V. Rudakov

Federal Research Center «Computer Science and Control» of the Russian Academy of Sciences; M.V.Lomonosov Moscow State University

Center for Big Data Storage and Analysis Technologies; Acad. RAS, Prof. Moscow, Russia

References

  1. Tilling L.M, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications 2006; 20 (3): 158-62. PMID: 16632235.
  2. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence. Acta Diabetol 2016; 53 (6): 879-89. doi: 10.1007/s00592-016-0880-y. PMID: 27393005.
  3. Reginato A.M, Riera H, Vera M et al. Osteoarthritis in Latin America: Study of Demographic and Clinical Characteristics in 3040 Patients. J Clin Rheumatol 2015; 21 (8): 391-7. doi: 10.1097/RHU.0000000000000281. PMID: 26457483.
  4. Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38-44. doi: 10.14412/2074-2711-2018-2-38-44
  5. Лила А.М., Громова О.А., Торшин И.Ю. и др. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 88-97.
  6. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 2015; 245: 82-7.
  7. Bell G.A, Kantor E.D, Lampe J.W et al. Use of Glucosamine and Chondroitin in Relation to Mortality. Eur J Epidemiol 2012; 27 (8): 593-603.
  8. Lenox C.E, Lunn K.F. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. J Am Vet Med Assoc 2010; 236 (2): 183-6. doi: 10.2460/javma.236.2.183. PMID: 20074008.
  9. Stumpf J.L, Lin S.W. Effect of glucosamine on glucose control. Ann Pharmacother 2006; 40 (4): 694-8. doi: 10.1345/aph.1E658. PMID: 16569816.
  10. Torshin I.Yu, Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2015; 25 (4): 577-87.
  11. Torshin I.Y, Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016; 26 (2): 274-84.
  12. Torshin I.Yu, Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Рart 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016, 26 (3): 483-96.
  13. Torshin I.Y, Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Рart 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (1): 16-28.
  14. Torshin I.Yu, Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (2): 184-99.
  15. Garcilazo C, Cavallasca J.A, Musuruana J.L. Shoulder manifestations of diabetes mellitus. Curr Diabetes Rev 2010; 6 (5): 334-40. PMID: 20701586.
  16. Veronese N, Cooper C, Reginster J.Y et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 18: 30586-9. doi: 10.1016/j.semarthrit.2019.01.005. PMID: 30712918.
  17. Громова О.А., Торшин И.Ю., Лила А.М. и др. Молекулярные механизмы миопротективного действия хондроитина сульфата и глюкозамина сульфата при саркопении. Неврология, нейропсихиатрия, психосоматика. 2019; 11 (1): 117-24. doi: 10.14412/2074-2711-2019-1-117-124.
  18. Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Соврем. ревматология. 2018; 12 (2): 36-43.
  19. Торшин И.Ю., Громова О.А., Лила А.М. и др. Результаты постгеномного анализа молекулы глюкозамина сульфата указывают на перспективы лечения коморбидных заболеваний. Соврем. ревматология. 2018; 12 (4): 129-36.
  20. Shi H, Munk A, Nielsen T.S et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab 2018; 11: 160-77. doi: 10.1016/j.molmet.2018.02.010. PMID: 29525407.
  21. Lazarus M.B, Jiang J, Gloster T.M et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase. Nat Chem Biol 2012; 8 (12): 966-8. doi: 10.1038/nchembio.1109. PMID: 23103939; PMCID: PMC3508357.
  22. Lorenzo C, Festa A, Hanley A.J et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 2017; 40 (3): 375-82. doi: 10.2337/dc16-1569. PMID: 28031420.
  23. Banerjee P.S, Lagerlof O, Hart G.W. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1-15. doi: 10.1016/j.mam.2016.05.005. PMID: 27259471.
  24. Hwang S.Y, Shin J.H, Hwang J.S. Glucosamine exerts a neuroprotective effect via suppression of inflammationin rat brain ischemia/reperfusion injury. Glia 2010; 58 (15): 1881-92. doi: 10.1002/glia.21058. PMID: 20737476.
  25. Whelan S.A, Dias W.B, Thiruneelakantapillai L et al. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285 (8): 5204-11. doi: 10.1074/jbc.M109.077818. PMID: 20018868
  26. Baldini S.F, Steenackers A, Olivier-Van Stichelen S. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun 2016; 478 (2): 942-8. doi: 10.1016/j.bbrc.2016.08.056. PMID: 27520373.
  27. Park S, Pak J, Jang I, Cho J.W. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun 2014; 453 (2): 208-12. doi: 10.1016/j.bbrc.2014.05.047. PMID: 24858682.
  28. Al-Kurdi Z.I, Chowdhry B.Z, Leharne S.A et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther 2015; 9: 6167-76. doi: 10.2147/DDDT.S91974. PMID: 26640369.
  29. Chien M.W, Lin M., Huang S.H et al. Glucosamine Modulates T Cell Differentiation through Down-regulating N-Linked Glycosylation of CD25. J Biol Chem 2015; 290 (49): 29329-44. doi: 10.1074/jbc.M115.674671. PMID: 26468284.
  30. Barrientos C, Racotta R, Quevedo L. Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats. Nutr Res 2010; 30 (11): 791-800. doi: 10.1016/j.nutres.2010.10.008. PMID: 21130299
  31. Balkan B, Dunning B.E. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994; 43 (10): 1173-9. PMID: 7926284.
  32. Simon R.R, Marks V, Leeds A.R, Anderson J.W. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14-27. doi: 10.1002/dmrr.1150. PMID: 21218504.
  33. Tannis A.J, Barban J, Conquer J.A. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12 (6): 506-11. doi: 10.1016/j.joca.2004.03.001. PMID: 15135147.
  34. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A Double-Blind, Placebo-Controlled Clinical Trial. Arch Rheumatol 2016; 31 (4): 340-5. doi: 10.5606/ArchRheumatol.2016.5632. PMID: 30375553.
  35. Gommans Y.M.M, Runhaar J, Jacobs M.L, Bierma-Zeinstra S.M.A. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. Am J Med 2017; 130 (6): 731-7.e6. doi: 10.1016/j.amjmed.2016.11.038. PMID: 28011309.
  36. Albert S.G, Oiknine R.F, Parseghian S et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800-3. doi: 10.2337/dc07-0545. PMID: 17682119.
  37. Scroggie D.A, Albright A, Harris M.D. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163 (13): 1587-90. doi: 10.1001/archinte.163.13.1587. PMID: 12860582.
  38. Nevado-Holgado A.J, Kim C.H, Winchester L et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016; 6 (11): e012177. doi: 10.1136/bmjopen-2016-012177. PMID: 27903560.
  39. Наумов А.В., Ткачева О.Н., Ховасова Н.О. Обострения хронической боли в спине у коморбидных больных: терапия на перспективу. РМЖ. Медицинское обозрение. 2018; 5: 35-42.
  40. Удовика М.И. Сравнительная эффективность инъекционных и пероральных симптоматических препаратов медленного действия в терапии первичного и посттравматического остеоартроза коленных суставов. РМЖ. 2017; 4: 446-50.
  41. Рандомизированное слепое многоцентровое плацебо-контролируемое клиническое исследование по изучению эффективности и безопасности препарата Сустагард® Артро, раствор для внутримышечного введения (ЗАО «ФармФирма “Сотекс”», Россия) у пациентов с остеоартрозом коленного сустава (гонартрозом) в параллельных группах, РКИ №60 от 12.02.2014, Фаза исследования III. Обращение к сайту 25 марта 2019. http://grls.rosminzdrav.ru
  42. Четина Е.В., Шарапова Е.П., Кашеварова Н.Г. и др. Экспрессия генов метаболизма глюкозы и деструкции суставов при развитии сахарного диабета у больных остеоартритом. Соврем. ревматология. 2019; 13 (1): 64-70.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies